Clinical Trials Browser

Phase 3 × OTHER × pertuzumab × Clear all

NCT06876714 2026-02-04

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT04193059 2025-11-26

PANSY

Phase 3 Active not recruiting

Breast Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Phase 3 Completed

Breast Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT02625441 2025-02-11

BOLD-1

Phase 3 Active not recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

Phase 3 Active not recruiting

Breast Neoplasms

NCT03595592 2024-03-06

APTneo

Phase 3 Active not recruiting

Invasive Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Phase 3 Recruiting

HER2-positive Metastatic Breast Cancer

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Phase 3 Recruiting

HER2 Positive Early Breast Cancer

NCT05188313 2022-06-24

TRAP-2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT04973319 2021-07-22

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Phase 3 Not yet recruiting

Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

Phase 3 Not yet recruiting

Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase 3 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms